HOUSTON - ResMed (NYSE: RMD, ASX: RMD), a global leader in digital health technologies and medical devices, has presented 13 new clinical studies at the SLEEP 2024 conference, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The studies highlighted the prevalence of sleep disorders such as insomnia and obstructive sleep apnea (OSA), and the effectiveness of positive airway pressure (PAP) therapy in treating these conditions.
One significant study, led by Adam Benjafield, PhD, vice president of clinical research at ResMed, revealed that approximately 17% of adults in the Americas suffer from insomnia. This finding underscores the need for public health initiatives to prioritize sleep health.
Another study, presented by Atul Malhotra, MD, of the University of California, San Diego, demonstrated that adherence to PAP therapy is associated with fewer hospitalizations and emergency room visits among patients with OSA and comorbid insomnia (COMISA). The data indicated that consistent use of PAP therapy could lead to better health outcomes for these patients.
Further research involving over 345,000 adults with OSA who had started PAP therapy found that nearly 17% also had depression, with a higher prevalence among women. The study, which included collaboration with Sanjay Patel, MD, of the UPMC Comprehensive Sleep Disorders Program, also showed that depression was linked to lower adherence to PAP therapy, especially in women, and was associated with a greater burden of comorbidities.
Carlos M. Nunez, MD, Chief Medical Officer at ResMed, emphasized the importance of these studies in advancing the understanding of sleep disorders and their treatment. He stated that the research contributes to the company's goal of helping people live healthier lives by expanding the body of knowledge in sleep medicine.
ResMed is known for its innovative solutions that aim to treat and keep people out of the hospital, such as cloud-connected medical devices for sleep apnea, COPD, and other chronic diseases. The company also offers out-of-hospital software platforms to support healthcare professionals and caregivers.
The information for this article is based on a press release statement from ResMed Inc.
In other recent news, ResMed has displayed a solid financial performance in the third quarter of fiscal year 2024, reporting a 7% increase in revenue, amounting to $1.2 billion. This growth was largely driven by a 5% increase in device sales and a 10% increase in masks and accessories sales. The company also reported a significant improvement in gross margin by 240 basis points to 58.5%. In addition, ResMed announced a quarterly dividend of $0.48 per share and plans to continue its share buyback program.
The company's strategic focus is on expanding the market for sleep and breathing health and investing in digital health technology. ResMed aims to grow the healthcare market by leveraging consumer tech and Big Pharma trends, with a specific focus on the non-invasive ventilation market. The company plans to continue share buybacks, reinvest in R&D, reduce debt, and consider strategic acquisitions.
Still, potential headwinds from the Middle East conflict could negatively impact Q4 gross margin by 30 to 50 basis points. Despite these potential challenges, ResMed remains confident in its ability to compete and take market share from competitors like Philips (LON:0LNG). These recent developments underscore ResMed's commitment to innovation and global expansion.
InvestingPro Insights
As ResMed (NYSE: RMD, ASX: RMD) continues to make strides in the field of sleep medicine, investors may take an interest in the company's financial health and performance metrics. According to InvestingPro data, ResMed has a market capitalization of 30.98 billion USD, indicating its substantial presence in the digital health technologies market. The company is trading at a P/E ratio of 32.42, reflecting investor confidence in its earnings potential.
InvestingPro Tips suggest that ResMed has a track record of raising its dividend for 12 consecutive years, showcasing its commitment to returning value to shareholders. Additionally, the company's cash flows can sufficiently cover interest payments, which is a reassuring sign of financial stability. Investors seeking more in-depth analysis will find that there are 13 additional InvestingPro Tips available, which can provide further insights into the company's performance and outlook.
For those interested in taking a closer look at ResMed's financials and future prospects, they can explore these tips on InvestingPro's dedicated page for ResMed at https://www.investing.com/pro/RMD. Moreover, users can take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to a wealth of investment information and analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.